Aquaculture

Farmed Tilapia Disease Management Welfare

Disease management in tilapia farming balances treatment efficacy with welfare considerations for affected fish and withdrawal periods for food safety.

Key Facts

Streptococcal disease is the most economically significant disease in tilapia globally
Columnaris disease causes skin and gill lesions with rapid mortality if untreated
Antibiotic use in tilapia farming is poorly regulated in many producing countries
Vaccination against streptococcosis has shown efficacy in reducing disease burden
Quarantine and biosecurity protocols prevent disease introduction to clean facilities

Welfare Considerations

Tilapia with untreated disease suffer from lethargy, skin lesions, respiratory compromise, and systemic illness. Preventive vaccination and biosecurity reduce the need for treatment and associated welfare costs.

What You Can Do

Choose tilapia with verified antibiotic-free or responsibly managed antibiotic certifications
Support development of vaccination programs for major tilapia diseases
Advocate for stronger antibiotic stewardship in tilapia producing countries